Lord, Abbett & Co’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-324,724
| Closed | -$19.4M | – | 607 |
|
|
2022
Q2 | $19.4M | Buy |
324,724
+10,980
| +3% | +$655K | 0.07% | 337 |
|
|
2022
Q1 | $22.8M | Buy |
313,744
+63
| +0% | +$4.58K | 0.06% | 355 |
|
|
2021
Q4 | $26.4M | Sell |
313,681
-116,225
| -27% | -$9.77M | 0.06% | 362 |
|
|
2021
Q3 | $38.8M | Buy |
429,906
+65,097
| +18% | +$5.87M | 0.09% | 318 |
|
|
2021
Q2 | $34.8M | Sell |
364,809
-13,017
| -3% | -$1.24M | 0.08% | 330 |
|
|
2021
Q1 | $43M | Buy |
+377,826
| New | +$43M | 0.11% | 292 |
|
|
2018
Q4 | – | Sell |
-273,479
| Closed | -$20.9M | – | 816 |
|
|
2018
Q3 | $20.9M | Buy |
+273,479
| New | +$20.9M | 0.06% | 469 |
|
|
2016
Q4 | – | Sell |
-157,176
| Closed | -$11.2M | – | 941 |
|
|
2016
Q3 | $11.2M | Sell |
157,176
-179,977
| -53% | -$12.8M | 0.03% | 547 |
|
|
2016
Q2 | $16.5M | Buy |
337,153
+181,270
| +116% | +$8.87M | 0.05% | 454 |
|
|
2016
Q1 | $9.87M | Sell |
155,883
-123,830
| -44% | -$7.84M | 0.03% | 575 |
|
|
2015
Q4 | $31.4M | Buy |
279,713
+48,133
| +21% | +$5.4M | 0.09% | 332 |
|
|
2015
Q3 | $22.3M | Sell |
231,580
-496,079
| -68% | -$47.8M | 0.07% | 389 |
|
|
2015
Q2 | $74.5M | Buy |
727,659
+99,327
| +16% | +$10.2M | 0.2% | 139 |
|
|
2015
Q1 | $39M | Buy |
628,332
+200,916
| +47% | +$12.5M | 0.1% | 320 |
|
|
2014
Q4 | $18.8M | Sell |
427,416
-150,215
| -26% | -$6.59M | 0.05% | 481 |
|
|
2014
Q3 | $32.7M | Buy |
577,631
+345,765
| +149% | +$19.6M | 0.08% | 343 |
|
|
2014
Q2 | $10.4M | Buy |
231,866
+177,722
| +328% | +$7.98M | 0.02% | 632 |
|
|
2014
Q1 | $2.65M | Buy |
+54,144
| New | +$2.65M | 0.01% | 896 |
|